Drug Trial Radar · NCT06702995
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
307
Planned (sponsor's estimate)
Start
Apr 19, 2023
Primary completion
Jul 13, 2027
Study completion Jul 13, 2027
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.
Conditions
- Metastatic Castrate-Resistant Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
XNW5004Drug
Oral continuous
enzalutamideDrug
enzalutamide 160 mg (four 40 mg capsules) orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ph Ib/IIa: Overall safety profile including adverse eventsTime frame: Baseline up to approximately 2 years
- Ph Ib/IIa: Recommended phase 2 doses (RP2D) of XNW5004 in combination with enzalutamideTime frame: Approximately 6 months
- Preliminary efficacy determination as evaluated by disease specific response criteriaTime frame: Baseline until disease progression or death or through study completion (approximately 2 years)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province
Jinan, Shandong, China · Recruiting
270 Dongan Road, Shanghai
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.